Mitoxantrone and Fludarabine in the treatment of patients with non-Hodgkin's lymphoma failing primary therapy with a doxorubicin or mitoxantrone-containing regimen

S. A. Gregory, J. Vose, M. Modiano, K. Kraemer, R. Rifkin, A. Rubin, T. Menduni, R. Ghalie

Research output: Contribution to journalArticlepeer-review

11 Scopus citations

Abstract

Patients with recurrent lymphoma of any grade were treated with mitoxantrone (12 mg/m2 given intravenously (IV) over 15-30 minutes on day 1) followed by fludarabine at a dose of (25 mg/m 2 given IV over 30 minutes on days 1-3) every 28 days fludarabine at a dose of (25 mg/m2 given IV over 30 minutes on days 1-3) every 28 days. All patients had failed one prior chemotherapy regimen that contained either doxorubicin or mitoxantrone, total dose not exceeding 350 mg/m2 doxorubicin or 80 mg/m2 mitoxantrone. mitoxantrone. Thirty one patients (22 with intermediate- or high-grade and 9 with low-grade NHL) were enrolled. Median age was 63 years (range: 21 to 87). The objective response rate for patients with intermediate/high-grade NHL was 55% (27% with CR) and 89% (56% with CR) for patients with low-grade NHL. Median time to disease progression was 5.1 months for patients with intermediate/high-grade NHL and 10.8 months for patients with low-grade NHL. Median time to death for patients with intermediate/high-grade disease was 11.4 months. Median time to death for patients with low-grade NHL was not calculable as only one death (due to respiratory failure) occurred in this group 6.5 months after study start. The regimen was well tolerated. Grade 3/4 neutropenia was reported in 80% (24 of 30) of patients and Grade 3/4 thrombocytopenia in 19% (6 of 31) of patients. Nine hospitalization for adverse events (primarily fever and neutropenia) occurred among eight patients, all with intermediate/high-grade NHL, during a total of 118 cycles of therapy. Further studies of this combination regimen in patients with intermediate/high-grade NHL and studies combined with monoclonal antibodies in low-grade NHL are warranted.

Original languageEnglish (US)
Pages (from-to)315-324
Number of pages10
JournalLeukemia and Lymphoma
Volume40
Issue number3-4
DOIs
StatePublished - 2001

Keywords

  • Fludarabine
  • GM-CSF
  • Mitoxantrone
  • Non-Hodgkin's lymphoma
  • Salvage therapy

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Mitoxantrone and Fludarabine in the treatment of patients with non-Hodgkin's lymphoma failing primary therapy with a doxorubicin or mitoxantrone-containing regimen'. Together they form a unique fingerprint.

Cite this